Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hs 578T | TNBC | Basal B | AG1024 | IGF1R | RTK | 7473.066 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0434 | -6.5378 | 2.3582 | |
| MDA-MB-361 | HER2amp | Luminal | Sulindac sulfide | COX1/2 | COX | 10643.136 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0432 | -6.6439 | 0.5141 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 12178.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0369 | 0.0948 | 0.6127 | |
| MDA-MB-175-VII | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7500.095 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0333 | -0.7066 | 0.4619 | |
| Hs 578T | TNBC | Basal B | Sirolimus | MTOR | MTOR | 7474.069 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0115 | -0.0565 | 2.5606 | |
| HCC1187 | TNBC | Basal A | LY294002 | PI3K | PI3K | 7812.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0475 | -56.7271 | 0.9642 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 12192.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0217 | -0.1880 | 0.4175 | |
| HCC1187 | TNBC | Basal A | PD184352 | MEK | MAPK | 7812.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0727 | 0.0526 | 0.9642 | |
| HCC1187 | TNBC | Basal A | PD184352 | MEK | MAPK | 7812.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0727 | 0.0526 | 0.9642 | |
| SUM225CWN | HER2amp | Basal A | Ro 32-0432 | PKC | PKC | 10579.142 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0168 | -0.2942 | 1.0435 | |
| BT-474 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 5905.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0377 | -5.6704 | 0.8461 | |
| BT-474 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 5906.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0021 | -0.0022 | 0.6586 | |
| LY2 | HR+ | Luminal | ZM-447439 | AURK | AURK | 10816.15 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.3031 | |
| MDA-MB-415 | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 9664.049 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.7193 | |
| SK-BR-3 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 11851.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0487 | 0.0000 | 1.4873 | |
| HCC3153 | TNBC | Basal A | PS-1145 | IKK | NFKB | 7467.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0386 | -3.7264 | 1.2393 | |
| MDA-MB-361 | HER2amp | Luminal | Ro 32-0432 | PKC | PKC | 10643.142 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0284 | -0.7438 | 0.5166 | |
| MDA-MB-453 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 9723.124 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0369 | -1.9688 | 0.9827 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 9254.049 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.8730 | |
| SUM225CWN | HER2amp | Basal A | Sulindac sulfide | COX1/2 | COX | 10579.136 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0370 | -2.7510 | 0.6876 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7902.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0247 | -0.1948 | 1.8686 | |
| MDA-MB-175-VII | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 10642.142 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0208 | 0.0000 | 0.5006 | |
| MCF 10F | NM | - | Cetuximab | EGFR | ErbB | 7872.042 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0054 | -0.0002 | 1.3632 |